文献速递垂体与肾上腺疾病

接受不同治疗方案的活动性肢端肥大症患者酰化/非酰化胃饥饿素比值相似

The Acylated/Unacylated Ghrelin Ratio Is Similar in Patients With Acromegaly During Different Treatment Regimens.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该研究评估了接受长效生长抑素类似物联合培维索孟治疗(n=60)的肢端肥大症患者的空腹血浆酰化胃饥饿素(AG)和非酰化胃饥饿素(UAG)水平及AG/UAG比值,并与培维索孟单药治疗和未经药物治疗的活动性肢端肥大症患者比较。结果显示联合治疗组AG和UAG水平显著低于其他两组,但AG/UAG比值在所有组间相似。

要点

  • 联合治疗组AG和UAG水平显著低于培维索孟单药组和未治疗组。
  • AG/UAG比值在所有组间相似,联合治疗未改变该比值。
  • 生长抑素类似物同时降低AG和UAG水平,可能不显著改变代谢。

核心结论

  • 尽管长效生长抑素类似物联合培维索孟治疗期间血浆AG和UAG被抑制,但AG/UAG比值仍保持相似。
  • 这表明生长抑素类似物同时降低AG和UAG水平,提示其未显著改变肢端肥大症患者的代谢。

研究设计与样本

  • 研究纳入接受长效生长抑素类似物联合培维索孟治疗的肢端肥大症患者(n=60),并设培维索孟单药治疗控制者和未经药物治疗的活动性肢端肥大症患者作为对照。
  • 采集空腹静脉血并直接稳定以抑制AG脱酰化,采用双抗体夹心酶免疫分析法测定血浆AG和UAG水平,并计算AG/UAG比值。

主要发现

  • 联合治疗组血浆AG中位数8.5 pg/mL(IQR 2.9至21.1 pg/mL),UAG中位数26.9 pg/mL(IQR 11.2至42.1 pg/mL)。
  • 培维索孟单药组AG中位数60.5 pg/mL(IQR 58.8至77.4 pg/mL),UAG中位数153.7 pg/mL(IQR 127.3至196.0 pg/mL)。
  • 未经药物治疗组AG中位数24.0 pg/mL(IQR 12.6至49.7 pg/mL),UAG中位数56.3 pg/mL(IQR 43.4至61.5 pg/mL)。
  • 联合治疗组AG和UAG水平显著低于培维索孟单药组和未经药物治疗组。
  • AG/UAG比值在所有组间相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) levels in acromegaly are limited. High AG/UAG ratios are linked with type 2 diabetes, obesity, and hyperphagia (e.g., in Prader-Willi syndrome). OBJECTIVE: To assess fasting plasma AG and UAG levels, and the AG/UAG ratio in acromegaly patients receiving combination treatment of long-acting somatostatin analogs (LA-SSAs) and pegvisomant (PEGV; n = 60). We used as controls acromegaly patients whose disease was controlled with PEGV monotherapy and medically naïve patients with active acromegaly. METHODS: Fasting venous blood samples were collected and directly stabilized to inhibit deacylation of AG. Plasma AG and UAG levels were determined by double-antibody sandwich enzyme immunoassay, and the AG/UAG ratio was calculated. RESULTS: Plasma AG and UAG levels were significantly lower in patients with acromegaly receiving combination treatment [median, interquartile range (IQR): AG: 8.5 pg/mL, 2.9 to 21.1 pg/mL; UAG: 26.9 pg/mL, 11.2 to 42.1 pg/mL] compared with patients using PEGV alone [AG: 60.5 pg/mL (IQR, 58.8 to 77.4 pg/mL); UAG: 153.7 pg/mL (IQR, 127.3 to 196.0 pg/mL)] and medically naïve patients with acromegaly [AG: 24.0 pg/mL (IQR, 12.6 to 49.7 pg/mL); UAG: 56.3 pg/mL (IQR, 43.4 to 61.5 pg/mL)]. However, AG/UAG ratios were similar in all groups. CONCLUSIONS: Although plasma AG and UAG are suppressed during combination treatment with LA-SSAs and PEGV, the AG/UAG ratio remained similar. This shows that SSAs decrease both AG and UAG levels, which suggests that they do not alter metabolism significantly in acromegaly patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Muhammad A, Delhanty PJD, Huisman M, et al. The Acylated/Unacylated Ghrelin Ratio Is Similar in Patients With Acromegaly During Different Treatment Regimens. J Clin Endocrinol Metab. 2017. PMID: 28402548. doi:10.1210/jc.2017-00147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。